000 01291 a2200337 4500
005 20250513151321.0
264 0 _c19990222
008 199902s 0 0 eng d
022 _a0586-7614
024 7 _a10.1093/oxfordjournals.schbul.a033333
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aYoung, C R
245 0 0 _aManagement of the adverse effects of clozapine.
_h[electronic resource]
260 _bSchizophrenia bulletin
_c1998
300 _a381-90 p.
_bdigital
500 _aPublication Type: Journal Article; Review
650 0 4 _aAgranulocytosis
_xchemically induced
650 0 4 _aAntipsychotic Agents
_xadministration & dosage
650 0 4 _aCardiovascular Diseases
_xchemically induced
650 0 4 _aCentral Nervous System Diseases
_xchemically induced
650 0 4 _aClozapine
_xadministration & dosage
650 0 4 _aDrug Administration Schedule
650 0 4 _aDyskinesia, Drug-Induced
_xprevention & control
650 0 4 _aGastrointestinal Diseases
_xchemically induced
650 0 4 _aHumans
650 0 4 _aSchizophrenia
_xdrug therapy
700 1 _aBowers, M B
700 1 _aMazure, C M
773 0 _tSchizophrenia bulletin
_gvol. 24
_gno. 3
_gp. 381-90
856 4 0 _uhttps://doi.org/10.1093/oxfordjournals.schbul.a033333
_zAvailable from publisher's website
999 _c9684009
_d9684009